2025.10.11
On June 30, 2025 Henlius and HanchorBio announced a collaboration to develop the SIRPα-Fc fusion protein HCB101 in mainland China (excluding Taiwan), key countries in Southeast Asia, as well as all counties in the Middle East and North Africa (MENA) region.
According to the agreement, HanchorBio will receive an upfront payment of USD 10 million, future milestone payments of up to USD 192 million, and the opportunity to receive 6% to 12% share of the sales.
JunHe reviewed, amended and negotiated the transaction documents. Throughout this deal, JunHe provided professional, efficient, and meticulous legal services, earning the HanchorBio's trust and recognition.
The lead partners for this project were Mr. ZHAO, Hao (Gerry) and Mr. TAO, Xudong.